

IL-6R Protein, Rhesus Macaque (HEK293, His)

Cat. No.:	HY-P73225
Synonyms:	Interleukin-6 receptor subunit alpha; IL-6R-alpha; IL-6R 1; gp80; CD126
Species:	Rhesus Macaque
Source:	HEK293
Accession:	XP_001114404.1 (L20-P365)
Gene ID:	716690
Molecular Weight:	Approximately 60-70 kDa

PROPERTIES

AA Sequence	<pre> L A P G G C P A Q E V A R G V L T S L P G D S V T L T C P G G E P E D N A T V H W V L R K P A V G S H L S R W A G V G R R L L L R S V Q L H D S G N Y S C Y R A G R P A G T V H L L V D V P P E E P Q L S C F R K S P L S N V V C E W G P R S T P S P T T K A V L L V R K F Q N S P A E D F Q E P C Q Y S Q E S Q K F S C Q L A V P E G D S S F Y I V S M C V A S S V G S K L S K T Q T F Q G C G I L Q P D P P A N I T V T A V A R N P R W L S V T W Q D P H S W N S S F Y R L R F E L R Y R A E R S K T F T T W M V K D L Q H H C V I H D A W S G L R H V V Q L R A Q E E F G Q G E W S E W S P E A M G T P W T E S R S P P A E N E V S T P T Q A P T T N K D D D N I L S R D S A N A T S L P V Q D S S S V P L P </pre>
Biological Activity	Measured by its binding ability in a functional ELISA. When Recombinant Human rhesus IL-6R is immobilized at 10 µg/mL (100 µL/well) can bind Biotinylated Recombinant Human IL6. The ED ₅₀ for this effect is 73.24 ng/mL.
Appearance	Lyophilized powder
Formulation	Lyophilized from a 0.2 µm filtered solution of PBS, pH 7.4.
Endotoxin Level	<1 EU/µg, determined by LAL method.
Reconstitution	It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH ₂ O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).
Storage & Stability	Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

DESCRIPTION

Background

IL-6 acts as both inflammatory factor and anti-inflammatory factor, fuels cancer progression through activating a series of downstream signalling cascade including gp130 (dimers), JAK/STAT, MAPK, and Akt^{[1][2]}.

IL-6R alpha (IL-6R α) as a part of the receptor for interleukin 6, is a type I transmembrane glycoprotein, which forms a complex with the type I transmembrane signal transducer Glycoprotein 130 (CD130) and regulates the biological activity of IL-6 with a low affinity^[3].

IL-6R alpha has 2 isoform including mL6R (the longer one) or sIL6R (the shorter one):

The mL6R is membrane-bound interleukin-6 receptor, has the potential to drive naive CD4⁺ T cells to the Th17 lineage, through 'cluster signaling' by dendritic cells^[4].

The sIL-6R is soluble interleukin-6 receptor subunit, cleaved from IL-6R alpha (IL-6R α) in activated CD4⁺ T cells by proteolysis, and serves as IL-6 agonist. sIL-6R binds membrane-bound IL6R and subunit IL6ST to activate regenerative and anti-inflammatory signal via IL-6 trans signaling and promotes pro-inflammatory properties of IL-6. The hydrolysis of IL-6R alpha is also called ectodomain shedding^[1].

IL-6R alpha involves in regulating cell growth and differentiation, and plays an important role in regulation of immune response, acute-phase reactions and hematopoiesis^[5].

However, IL-6R alpha shows tissue expression specificity in liver and some cells of the immune system, thus results a limitation of IL6 signaling^[6].

It's worth noting that IL-6R alpha dysregulation is implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases, and prostate cancer^{[7][8]}.

REFERENCES

- [1]. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. *J Biol Chem*. 2011 Dec 16;286(50):42959-70.
- [2]. Malemud, et al. Defective JAK-STAT Pathway Signaling Contributes to Autoimmune Diseases. *Curr Pharmacol Rep* 4, 358-366.
- [3]. Larsen JV, et al. SorLA in Interleukin-6 Signaling and Turnover. *Mol Cell Biol*. 2017 May 16;37(11):e00641-16.
- [4]. Kang S, et al. Targeting Interleukin-6 Signaling in Clinic. *Immunity*. 2019 Apr 16;50(4):1007-1023.
- [5]. Giannitrapani L, et al. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. *Ann N Y Acad Sci*. 2002 Jun;963:46-52.
- [6]. Arnold P, et al. Joint Reconstituted Signaling of the IL-6 Receptor via Extracellular Vesicles. *Cells*. 2020 May 24;9(5):1307.
- [7]. Mishra AK, et al. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. *Leukemia*. 2019 Nov;33(11):2695-2709.
- [8]. Gruber CN, et al. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). *Cell*. 2020 Nov 12;183(4):982-995.e14.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA